GUERBET 
By The Board of Directors of the Guerbet company, which met on Monday 17 October under the chairmanship of Mr. Jean-Jacques Bertrand, has appointed Dr. Yves L’Epine as CEO of Guerbet.
The Board of Directors unanimously thanked Mr. Jean-Jacques Bertrand for having carried out, in addition to his duties as Chairman of the Board of Directors, that of CEO during the time needed to recruit a new CEO following the sudden death of Mr. Bernard Massiot on
28 May 2011.
Yves L’Epine is 51 years old, is a doctor of cardiology and a graduate of the INSEAD business school. He started his career at Sandoz and went on to assume General Management responsibilities with Novartis, Takeda and Abbott, principally in France and then elsewhere in Europe.
He will take up his position at the end of November.
The Board of Directors has reiterated its confidence in Guerbet’s development prospects and
in the capacity of the Group’s teams to convert these into success.
Commenting on the appointment, Mr. Jean-Jacques Bertrand declared “Bernard Massiot gave a new impulse to the Group and initiated numerous transformations. Yves L’Epine shall ensure the continuity of the work undertaken and will make it his duty to enable Guerbet to succeed in its ambition to be a major player in medical imaging. On the strength of his management experience, both in France and internationally, his intimate knowledge of the pharmaceuticals industry and his medical competence, Yves will have the ability to succeed in Guerbet's sustainable growth and innovation strategy.”
Yves L’Epine stated: “I am proud to be contributing to the future of the Guerbet Group, the employees and shareholders of which have a genuine ambition of development in the service of patients and health systems.”
About Guerbet
Guerbet is the only pharmaceutical group totally dedicated to medical imaging on the world market. It has a comprehensive range of X-ray, MRI and nuclear medicine imaging products to enhance overall patient care. Its products facilitate diagnosis and the preparation of treatment strategies for major pathologies (cardiovascular diseases, cancers, inflammatory and degenerative diseases).
To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales. The programs on MRI and nuclear medicine modalities are central to Guerbet’s research priorities.
Guerbet has a very strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.
Guerbet, listed on the Euronext Paris Eurolist (compartment B), posted sales of €352 million
in 2010 with a total headcount of 1300.
For more information about Guerbet, please go to www.guerbet.com .
Tel: + 33 (0)1 45 91 50 03
anne-laure.delasalle@guerbet-group.com
